Furthermore, experimental evidence demonstrates that an activated MET oncogene—known as a key regulator of the resistance of NSCLC to gefitinib (an EGFR inhibitor)—promotes cancer-associated thrombosis [57,58]. This evidence concerns the gene MET and cancer.